Unique ID issued by UMIN | UMIN000053540 |
---|---|
Receipt number | R000061058 |
Scientific Title | Outcomes of carbon ion radiotherapy and photon stereotactic body radiotherapy using Cyberknife for uveal melanoma |
Date of disclosure of the study information | 2024/02/06 |
Last modified on | 2024/02/05 08:53:24 |
Outcomes of carbon ion radiotherapy and photon stereotactic body radiotherapy using Cyberknife for uveal melanoma
Comparative Study of uveal melanoma
Outcomes of carbon ion radiotherapy and photon stereotactic body radiotherapy using Cyberknife for uveal melanoma
Comparative Study of uveal melanoma
Japan | Asia(except Japan) |
uveal melanoma
Ophthalmology | Radiology |
Malignancy
NO
The purpose of this study is to compare the treatment outcomes of Cyberknife-based SBRT and CIRT for uveal melanoma patients. With CIRT recently introduced as a first in South Korea at Yonsei Medical Center, it has become a significant issue, and If the superiority of CIRT is demonstrated compared to conventional photon-based radiation therapy in the treatment of uveal melanoma, it could establish itself as a highly beneficial treatment option for these patients in the future.
Safety,Efficacy
overall survival
Local control rate, adverse events, recurrence-free survival, eye preservation rate
Observational
Not applicable |
Not applicable |
Male and Female
Cases of choroidal malignant melanoma treated with carbon ion beam therapy at QST Hospital from April 1992 to October 2021, and cases treated with photon beam therapy using stereotactic irradiation with CyberKnife at Yonsei University Severance Hospital
(i) Cases in which the research subject or his/her representative refuses the use of clinical data for this study.
(ii) Recurrent cases, metastatic cases, cases with a history of irradiation to the head and neck region, and cases in which the comorbid invasive cancer has not remained disease-free for at least 3 years (excluding malignant tumors that do not significantly affect prognosis, such as thyroid cancer, MALT lymphoma, basal cell carcinoma of the skin, and early stage prostate cancer).
(iii) Patients who are lost to follow-up without at least one post-treatment follow-up visit.
380
1st name | Masaru |
Middle name | |
Last name | Wakatsuki |
QST Hospital, National Institute for Quantum Science and Technology
Department of Diagnostic Radiology and Radiation Oncology
263-8555
4-9-1 Anagawa, Inage-ku, Chiba
043-206-3306
wakatsuki.masaru@qst.go.jp
1st name | Masaru |
Middle name | |
Last name | Wakatsuki |
QST Hospital, National Institute for Quantum Science and Technology
Department of Diagnostic Radiology and Radiation Oncology
263-8555
4-9-1 Anagawa, Inage-ku, Chiba
043-206-3306
wakatsuki.masaru@qst.go.jp
National Institute for Quantum Science and Technology
National Institute for Quantum Science and Technology
Japanese Governmental office
National Institute for Quantum Science and Technology
4-9-1 Anagawa, Inage-ku, Chiba
043-206-4706
helsinki@qst.go.jp
NO
国立研究開発法人量子科学技術研究開発機構QST病院
延世大学セブランス病院
2024 | Year | 02 | Month | 06 | Day |
Unpublished
Enrolling by invitation
2024 | Year | 01 | Month | 22 | Day |
2024 | Year | 01 | Month | 22 | Day |
2024 | Year | 02 | Month | 01 | Day |
2024 | Year | 02 | Month | 01 | Day |
This is a two-center, retrospective cohort study of patients with choroidal malignant melanoma treated with carbon ion beam therapy and stereotactic irradiation.
2024 | Year | 02 | Month | 05 | Day |
2024 | Year | 02 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061058